CNS Drugs
Journal Title
- CNS Drugs
ISSN
- E 1179-1934 | P 1172-7047 | 1172-7047 | 1179-1934
Publisher
- Adis International Ltd.
- Springer Nature
Listed on(Coverage)
| JCR | 1997-2019 |
|---|---|
| SJR | 1999-2019 |
| CiteScore | 2011-2019 |
| SCI | 2010-2019 |
| SCIE | 2010-2021 |
| CC | 2016-2021 |
| SCOPUS | 2017-2020 |
| MEDLINE | 2016-2021 |
| EMBASE | 2016-2020 |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- NEW ZEALAND
Aime & Scopes
- CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes: /// Overviews of contentious or emerging issues. /// Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses. /// Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. /// Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry. /// Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances. All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.